Code
NTG-LDPX-02CX
Profile
Active-Compendium
81455x1
81450x1
Clinical
Oncology,Pathology
<p><b>Bone Marrow Aspirate:</b> 2-3 mL in EDTA tube.<br> <b>Peripheral Blood:</b> 3-5 mL in EDTA tube.<br> <b>H&E slide:</b> Required, plus paraffin block.<br> <b>Cut Slides:</b> H&E slide (required) plus 10-14 unstained slides cut at 5+ microns.<br> <b>Note on FFPE:</b> Paraffin block is preferred. Do not use zinc fixatives. If submitting slides, please use positively-charged slides and 10% NBF fixative. Block and slide identifiers should be clearly written and match exactly with the specimen ID and specimen labeling as noted on the requisition.<br> <b>Do not use:</b> Mercury fixatives (B5). Highly acidic or prolonged decalcification processes will not yield sufficient nucleic acid to accurately perform molecular studies.<br> <b>Note:</b> Test is TNA-based. Please select Extract & Hold - TNA if specimen hold service is desired.</p>
Flag Active
True
Orderable Test Description
<p>The NeoTYPE Lymphoid Disorders Profile is intended as an aid in the diagnosis and subclassification of lymphoid neoplasms as well as to identify potential therapies based on the patient's unique molecular drivers.</p>
<p>This panel is designed to detect DNA mutations across 128 genes, associated with multiple lymphoma and leukemia subtypes, through next-generation sequencing (NGS). It includes the following genes:<br><br>DNA NGS (SNV/Indel):<br>ABL1, ABL2, ALK, ARHGEF1, ARID1A, ARID2, ASXL1, ATM, B2M, BCL2, BCL6, BCOR, BIRC3, BRAF, BTK, CARD11, CCND1, CCND2, CCND3, CD274, CD79A, CD79B, CDKN1B, CDKN2A, CDKN2B, CIITA, CREBBP, CRLF2, CSF1R, CTCF, CTNNB1, CXCR4, DDX3X, DIS3, DNMT3A, EBF1, EGR1, EP300, EPOR, ETV6, EZH2, FAM46C, FAS, FAT1, FBXW7, FGFR3, FOXO1, GATA3, GNA13, GNAI2, HIST1H1E, HRAS, ID3, IDH1, IDH2, IKBKB, IKZF1, IKZF3, IRAK4, ITPKB, JAK1, JAK2, JAK3, KLF2, KMT2D, KRAS, MALT1, MAP2K1, MAP3K14, MAPK1, MED12, MEF2B, MYC, MYCN, MYD88, NF1, NFKBIE, NOTCH1, NOTCH2, NOTCH3, NRAS, NT5C2, P2RY8, PDGFRB, PHF6, PIK3CA, PIK3CD, PIK3R1, PIM1, PLCG1, PLCG2, POT1, PPM1D, PRDM1, PRPS1, PTEN, PTPN11, RB1, REL, RHOA, RIPK1, RPS15, RUNX1, S1PR2, SAMHD1, SETD2, SF3B1, SGK1, SH2B3, SOCS1, SPEN, STAT3, STAT5B, STAT6, TBL1XR1, TCF3, TET2, TLR2, TNFAIP3, TNFRSF14, TP53, TRAF2, TRAF3, UBR5, WT1, XPO1, ZFHX4, ZMYM3<br><br>Test Interpretation: Reports include a summary interpretation of all results.</p>
<p>This panel is designed to detect DNA mutations across 128 genes, associated with multiple lymphoma and leukemia subtypes, through next-generation sequencing (NGS). It includes the following genes:<br><br>DNA NGS (SNV/Indel):<br>ABL1, ABL2, ALK, ARHGEF1, ARID1A, ARID2, ASXL1, ATM, B2M, BCL2, BCL6, BCOR, BIRC3, BRAF, BTK, CARD11, CCND1, CCND2, CCND3, CD274, CD79A, CD79B, CDKN1B, CDKN2A, CDKN2B, CIITA, CREBBP, CRLF2, CSF1R, CTCF, CTNNB1, CXCR4, DDX3X, DIS3, DNMT3A, EBF1, EGR1, EP300, EPOR, ETV6, EZH2, FAM46C, FAS, FAT1, FBXW7, FGFR3, FOXO1, GATA3, GNA13, GNAI2, HIST1H1E, HRAS, ID3, IDH1, IDH2, IKBKB, IKZF1, IKZF3, IRAK4, ITPKB, JAK1, JAK2, JAK3, KLF2, KMT2D, KRAS, MALT1, MAP2K1, MAP3K14, MAPK1, MED12, MEF2B, MYC, MYCN, MYD88, NF1, NFKBIE, NOTCH1, NOTCH2, NOTCH3, NRAS, NT5C2, P2RY8, PDGFRB, PHF6, PIK3CA, PIK3CD, PIK3R1, PIM1, PLCG1, PLCG2, POT1, PPM1D, PRDM1, PRPS1, PTEN, PTPN11, RB1, REL, RHOA, RIPK1, RPS15, RUNX1, S1PR2, SAMHD1, SETD2, SF3B1, SGK1, SH2B3, SOCS1, SPEN, STAT3, STAT5B, STAT6, TBL1XR1, TCF3, TET2, TLR2, TNFAIP3, TNFRSF14, TP53, TRAF2, TRAF3, UBR5, WT1, XPO1, ZFHX4, ZMYM3<br><br>Test Interpretation: Reports include a summary interpretation of all results.</p>
Orderable Turn Around Time
14 Days
Keywords
Orderable Biomarkers
NY Approved
True
Orderable Biomarkers JSON
{"DNA Sequencing": {"SNVs + Indels": ["KMT2D", "MAP2K1", "PIK3CD", "PIM1", "MED12", "MEF2B", "MYC", "PPM1D", "MYCN", "NF1", "NOTCH2", "NOTCH3", "PIK3R1", "PRDM1", "REL", "RHOA", "RB1", "SETD2", "SOCS1", "SPEN", "STAT3", "STAT5B", "TNFAIP3", "TNFRSF14", "TCF3", "XPO1", "TRAF2", "ARHGEF1", "CIITA", "DDX3X", "EBF1", "ABL1", "EGR1", "ABL2", "CDKN2A", "CRLF2", "CSF1R", "EPOR", "FGFR3", "GNAI2", "IKZF1", "STAT6", "H1-4", "JAK1", "JAK2", "JAK3", "IKBKB", "IKZF3", "IRAK4", "ITPKB", "KLF2", "PDGFRB", "SH2B3", "B2M", "NFKBIE", "TP53", "ASXL1", "NT5C2", "BRAF", "BCOR", "P2RY8", "DNMT3A", "ETV6", "EZH2", "HRAS", "IDH1", "IDH2", "PLCG1", "POT1", "KRAS", "NRAS", "PHF6", "PTPN11", "RUNX1", "PRPS1", "SF3B1", "TET2", "WT1", "RIPK1", "RPS15", "S1PR2", "SAMHD1", "SGK1", "TBL1XR1", "TLR2", "TRAF3", "DIS3", "UBR5", "ZFHX4", "ZMYM3", "ARID1A", "ATM", "CTNNB1", "GATA3", "PIK3CA", "PTEN", "FAM46C", "FOXO1", "BCL2", "BIRC3", "BTK", "CARD11", "CD79B", "CXCR4", "MYD88", "NOTCH1", "PLCG2", "FBXW7", "ALK", "ARID2", "ID3", "BCL6", "CCND1", "CCND2", "CCND3", "CD274", "CD79A", "CDKN1B", "CDKN2B", "CREBBP", "CTCF", "MALT1", "MAP3K14", "MAPK1", "EP300", "FAS", "FAT1", "GNA13"]}}
Keywords string
Heme Cancers, Hematologic Disorders, Hematologic Malignancies, Lymphoid Disorders, lymphoma, leukemia NeoTYPE® Lymphoid Disorders Profile
Title URL
neotype-lymphoid-disorders-profile
Clinical Significance
The NeoTYPE Lymphoid Disorders Profile is intended as an aid in the diagnosis and subclassification of lymphoid neoplasms as well as to identify potential therapies based on the patient's unique molecular drivers. The profile includes analysis of genes known to be recurrently mutated in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Richter's syndrome (RS), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), lymphoplasmacytic lymphoma (LPL), hairy cell leukemia (HCL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), double-hit lymphoma (DHL), and various T-cell neoplasms.
Storage and transportation
Refrigerate specimen. Do not freeze. Use cold pack for transport, making sure cold pack is not in direct contact with specimen. NYS clients please provide date and time of collection. Please select Extract & Hold - TNA if specimen hold service is desired.